Sorrento Therapeutics, Inc.
SRNE · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $4 | $7 |
| - Cash | $70 | $38 | $24 | $71 |
| + Debt | $208 | $184 | $135 | $182 |
| Enterprise Value | $140 | $148 | $115 | $118 |
| Revenue | $15 | $16 | $16 | $17 |
| % Growth | -7.5% | 4.2% | -10.4% | – |
| Gross Profit | $7 | $11 | $2 | $9 |
| % Margin | 43.7% | 68.1% | 12% | 52.5% |
| EBITDA | -$99 | -$137 | -$205 | -$87 |
| % Margin | -662.1% | -841.4% | -1,314.1% | -498.5% |
| Net Income | -$95 | -$140 | -$224 | -$91 |
| % Margin | -633.7% | -859.1% | -1,434.5% | -521.2% |
| EPS Diluted | -0.17 | -0.26 | -0.51 | -0.2 |
| % Growth | 34.6% | 49% | -155% | – |
| Operating Cash Flow | -$56 | -$49 | -$68 | -$61 |
| Capital Expenditures | -$0 | -$0 | -$5 | -$4 |
| Free Cash Flow | -$56 | -$50 | -$73 | -$65 |